A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

Clinical trial NCT07241039 · RECRUITING

Trial details

NCT number: NCT07241039
Sponsor: AbbVie
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Squamous Tumors

Start date: 2025-11-20
Primary completion: 2029-04-01
Enrollment: 220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.